In addition to examining the more traditional effectiveness criteria- those rooted in market impacts- the model considers a number of alternative effectiveness criteria, including political effectiveness, capacity-building.
Therefore, and given the robustness of our findings against alternative effectiveness inputs (i.e. 5 times smaller), we consider it safe to conclude that the intervention is cost-saving for the general group of cancer survivors who are eligible for multidisciplinary return-to-work interventions.
In order to evaluate this alternative, the effectiveness of VI as a tool in porous matrix formulation is analyzed.
We compared alternative cost effectiveness ratios on the basis of these imputed full sample costs and outcomes with the base case ratios.
Given it was unclear what was the relevant source of heterogeneity in the evidence base, alternative clinical effectiveness models were evaluated.
The cost-effectiveness of IVIG appears within the borderline region of estimates considered to represent value for money in the NHS, but these results are associated with significant uncertainty and appear highly sensitive to the alternative clinical effectiveness models applied.
For the alternative clinical effectiveness models, the ICER estimates vary between £16,177 per QALY to IVIG being dominated by SC alone (that is IVIG being both less effective and more costly).
On the basis of an observational case study of 27 hard-to-heal ulcers an alternative cost-effectiveness estimate was established, using a prospective analysis of resource use and cost for Dermagraft.
31 32 There is a need for comprehensive evaluation of the effects of alternative managements, comparing clinical effectiveness, psychological and other after effects, and cost effectiveness.
In case the strategy is more costly and more effective, or less costly and less effective than the alternative, incremental cost-effectiveness ratios (ICERs) were calculated from each model by dividing the incremental costs by the incremental QALYs.
We conclude that postponement of adverse health outcomes is an alternative measure of effectiveness that seems to allow laypersons to discriminate between levels of effectiveness.
